Q-omics provides the consensus-scored TSPAN12 profile across patient tissues and cancer cell-line models. TSPAN12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSPAN12 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TSPAN12 RNA expression shows 19,123 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TSPAN12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN12 survival associations across molecular data types. TSPAN12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN12 RNA expression–survival associations across cancer types. High TSPAN12 expression shows unfavorable associations in UVM, ESCA and THCA, but favorable associations in KIRC, ACC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSPAN12 RNA expression.
This table summarizes TSPAN12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TSPAN12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN12 shows lower tumor expression in THCA, KICH, LUSC, LUAD, LIHC and HNSC. The THCA box plot shows higher TSPAN12 RNA expression in normal versus tumor tissue (log2 FC = −1.208, t-test p < 0.001).
This table shows molecular features associated with TSPAN12 in patient tissues and cancer cell lines. In patient samples, TSPAN12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
